Feed Top Reports Pricing

⌘K

16:45:33·27d

SECFiling

SEC Form 10-K filed by Humacyte Inc.

HUMA· Humacyte Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

HUMA
Humacyte Inc.
Health Care

Recent analyst ratings

Aug 27UpdateBarclays$3.50
May 14UpdateH.C. Wainwright$4.00
Dec 20UpdateH.C. Wainwright$15.00
Dec 11UpdateH.C. Wainwright$6.00
Aug 14UpdatePiper Sandler$3.50
Jun 22UpdateCantor Fitzgerald$6.00

Related

PR1d
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
PR2d
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
SEC6d
SEC Form PRE 14A filed by Humacyte Inc.
PR27d
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
PR28d
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
SEC31d
Amendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.
PR31d
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
SEC35d
Humacyte Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022